Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aclaris Therapts 701 LEE ROAD SUITE 103 WAYNE PA 19087 USA

www.aclaristx.com Employees: 64 P: 484-324-7933

Sector:

Medical

Description:

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 478,885
Enterprise Value, $K 454,315
Shares Outstanding, K 108,345
Float, K 102,278
% Float 94.40%
Short Interest, K 4,346
Short Float 4.01%
Days to Cover 4.62
Short Volume Ratio 0.36
% of Insider Shareholders 5.60%
% of Institutional Shareholders 98.34%

Financials:

Annual Sales, $ 18,720 K
Annual Net Income, $ -132,070 K
Last Quarter Sales, $ 3,300 K
Last Quarter Net Income, $ -14,610 K
EBIT, $ -66,410 K
EBITDA, $ -65,600 K

Growth:

1-Year Return 70.00%
3-Year Return -74.71%
5-Year Return -78.70%
5-Year Revenue Growth 342.55%
5-Year Earnings Growth 64.44%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.12 on 11/06/25
Next Earnings Date 02/26/26
Earnings Per Share ttm -0.47
EPS Growth vs. Prev Qtr 7.69%
EPS Growth vs. Prev Year -9.09%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ACRS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -39.73%
Return-on-Assets % -27.98%
Profit Margin % -705.50%
Debt/Equity 0.00
Price/Sales 32.54
Price/Cash Flow N/A
Price/Book 2.36
Book Value/Share 1.11
Interest Coverage -4.35
60-Month Beta 0.41
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar